CD82

Across TCGA pan-cancer cohorts, CD82 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CD82’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where CD82 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CD82 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

PDAC, HNSC, and LUAD are the cancer types where CD82 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD82 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+1.196	<.001	8	view →
HNSC	All	All	−0.340	<.001	8	view →
LUAD	Female	All	−0.465	<.001	6	view →
LSCC	All	II,III,IV	−0.358	<.001	5	view →
COAD	All	II,III,IV	+0.195	.010	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CD82–PDAC

Open the PDAC breakdown →